Classic cancer treatments are completely indiscriminate - they tend to kill any dividing cell in sight - while cancers are unique to each individual. A number of companies are thus taking the opposite approach of creating autologous therapies using the patient's tumor cells to produce totally individualized therapies. But this can create issues of manufacturing and scale.

Like Goldilocks, Wilex Biotechnology GmbH is trying to combine the best of both approaches, aiming to create off-the-shelf drugs that patients will receive based on the molecular characterization of their primary tumor.